Toxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B.
about
Functional linkage between genes that regulate osmotic stress responses and multidrug resistance transporters: challenges and opportunities for antibiotic discoveryHematological toxicities associated with amphotericin B formulations.Pharmacodynamics of amphotericin B deoxycholate, amphotericin B lipid complex, and liposomal amphotericin B against Aspergillus fumigatus.Prevalence and Hospital Management of Amphotericin B Deoxycholate-Related Toxicities during Treatment of HIV-Associated Cryptococcal Meningitis in South AfricaCase-control study and case series of pseudohyperphosphatemia during exposure to liposomal amphotericin B.Liposomal Amphotericin B (AmBisome(®)): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions.Safety, Tolerability, and Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Pediatric Patients.Clinical pharmacology of antifungal agents to overcome drug resistance in pediatric patients.Antifungal-Associated Drug-Induced Cardiac Disease.Comparison between liposomal formulations of amphotericin B.Galleria mellonella as a host model to study Aspergillus terreus virulence and amphotericin B resistance.Unique aggregation of conjugated amphotericin B and its interaction with lipid membranes.Invasive Fungal Sinusitis Involving the Orbital Apex in a Patient with Chronic Renal Failure.Chemogenomic profiling of the fungal pathogen Candida albicans.A Phase 3 Study of Micafungin Versus Amphotericin B Deoxycholate in Infants with Invasive Candidiasis.
P2860
Q27023447-B72305C3-4816-44FC-AE5D-A70B16FB3DB0Q33420040-6ED44202-EA24-4D8E-8B88-364F16CFBB7FQ35385786-23E34822-0190-4D00-9586-7AD17C577B84Q36088679-A8629762-B321-43B6-B307-7A58659D0F68Q36158204-676B0674-C560-4473-B6D4-0C086E239366Q36868273-B9C6A725-DF82-4349-AC3B-E22856066F81Q37613070-C30C8EA7-ACC4-430E-8113-DBE01F202714Q38314467-66D88A43-550F-4875-85C6-4ABC9AD11A81Q38633109-9E40502C-B16E-4CB9-B807-07DA0A7544C2Q38696930-DE520F68-6516-4CD9-BBF0-4A6B5B35565EQ40801674-B92B219A-FF3C-4303-9645-FDE575FE8635Q40851105-1A3212D1-DA0E-4B61-A869-92DC6016BD4BQ41119394-D9BC9577-F899-43CB-9F36-0D600698FB31Q46248402-69B32D16-7ABE-40B8-A121-97E67F9F0716Q53834039-D2F9781D-1D4D-4993-82CF-A90BB7E731C0
P2860
Toxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B.
description
2013 nî lūn-bûn
@nan
2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Toxicokinetic and mechanistic ...... y of liposomal amphotericin B.
@ast
Toxicokinetic and mechanistic ...... y of liposomal amphotericin B.
@en
type
label
Toxicokinetic and mechanistic ...... y of liposomal amphotericin B.
@ast
Toxicokinetic and mechanistic ...... y of liposomal amphotericin B.
@en
prefLabel
Toxicokinetic and mechanistic ...... y of liposomal amphotericin B.
@ast
Toxicokinetic and mechanistic ...... y of liposomal amphotericin B.
@en
P2860
P1476
Toxicokinetic and mechanistic ...... ty of liposomal amphotericin B
@en
P2093
Angela S Loo
Thomas J Walsh
P2860
P304
P356
10.1517/14740338.2013.827168
P407
P577
2013-08-10T00:00:00Z